The Latest Biology News And Medical NewsBiology News 2Health News 2Biology News 3Health News 3
HOME >> BIOLOGY >> NEWS
Phillip A. Sharp to present 2004 Ullyot Public Affairs Lecture at Chemical Heritage Foundation

in nonsense segments that are edited out by cells in the course of utilizing genetic information is important in understanding the genetic causes of cancer and other diseases. Sharp's research opened an entirely new area in molecular biology and forever changed the field. For this work he was awarded the 1993 Nobel Prize in Physiology or Medicine.

Sharp is cofounder of Biogen (now Biogen Idec) and a member of its board of directors. He also cofounded Alnylam Pharmaceuticals, where he serves on the board of directors and chairs the scientific board.

A native of Kentucky, Sharp earned his B.A. from Union College in his home state, followed by a Ph.D. in chemistry from the University of Illinois at Urbana. He has authored more than 300 scientific papers and served on many scientific committees, including the National Cancer Institute's Advisory Board and the Scientific Advisory Committee of the Dana-Farber Cancer Institute. He has been a member of the Sloan Foundation Board of Trustees, the Ludwig Institute Scientific Advisory Board, the Massachusetts General Hospital Board of Trustees, and the Scientific and Medical Advisory Board of the Huntsman Cancer Foundation. In addition to the Nobel Prize, his work has been honored with the Benjamin Franklin Medal of the American Philosophical Society, the Alfred P. Sloan, Jr., Prize for Cancer Research, the Louisa Gross Horwitz Prize, and the Albert Lasker Basic Medical Research Award, among others. He received the Biotechnology Heritage Award from CHF in 2002, along with his Biogen cofounder, Walter Gilbert. Sharp is an elected member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences.


'"/>

Contact: Neil Gussman
neilg@chemheritage.org
717-314-2494
Chemical Heritage Foundation
13-Oct-2004


Page: 1 2

Related biology news :

1. Phillip A. Sharp to receive the 2007 Winthrop-Sears Award
2. ConocoPhillips establishes $22.5M biofuels research program at Iowa State
3. Researchers gain support from Merck Sharp & Dohme for novel area of diabetes research
4. Illinois researchers presenting at ASPB Annual Meeting in Chicago, July 7-11
5. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions
6. 18-year-old Singaporean student to present stem cell research paper at conferences in US and UK
7. WPI professor to represent American Mathematical Society at exhibition on science funding
8. SNM presents awards on Capitol Hill
9. Duetting birds with rhythm present a greater threat
10. ESA presents the sharpest ever satellite map of Earth
11. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference

Post Your Comments:
(Date:11/23/2009)...itute of General Medical Sciences (NIGMS), part of...ting $42.3 million for grants in scientific areas ...eveloped the GO grant program to stimulate biomedi...by the American Recovery and Reinvestment Act (Rec...promise to have a significant impact on a field of...
(Date:11/23/2009)... Casabona is Director of the Interuniversity Profe...iversity and the University of the Basque Country....ut also has other experts such as researchers in t...specialists in ethics. , The Interuniversity Pro...versities of Deusto and the Basque Country was cre...
(Date:11/23/2009)...available in German . , Of all global carbo...the atmosphere where it contributes to global warm...rrestrial ecosystems such as forests, grasslands a...aquatic and terrestrial ecosystems is considered o...cing climate change. However, new greenhouse gas b...
Breaking Biology News(10 mins):NIGMS invests in scientific Grand Opportunities with Recovery Act funds 2NIGMS invests in scientific Grand Opportunities with Recovery Act funds 3Research and legislation should go hand in hand, as much as possible 2Intensive land management leaves Europe without carbon sinks 2LSUHSC contributes to revealing targets to reduce racial disparity in prostate cancer deaths 53092 1LSUHSC contributes to revealing targets to reduce racial disparity in prostate cancer deaths 53092 2LSUHSC contributes to revealing targets to reduce racial disparity in prostate cancer deaths 53092 3Naming evolutions winners and losers 9412 1Naming evolutions winners and losers 9412 2Naming evolutions winners and losers 9412 3Scientists discover Amazon river is 11 million years old 9407 1
(Date:11/23/2009)...Calif.,Nov.23/PRNewswire/--PearlTherapeuticsInc.,a...ctsforthetreatmentofchronicrespiratorydiseases,tod...sBoardofDirectors.Mr.Rosenhas25yearsofexperiencein...ingkeyrolesatGileadSciencesandALZACorporation.Hisa...ardtosix. ,, "Howiebringsawealthofproductdevelo...
(Date:11/20/2009)..., , , , , , , ,...AUDIO: , A team of scientists from Washington...a, Cold Spring Harbor Laboratory and Iowa State Un...The... , , Click here for more in... , , , , , , , ...
(Date:11/20/2009)..., Nov. 20 Veridiam (www.veridiam.c...ize company category at the 2009 Workplace Excelle...ego Society for Human Resources Management and rec...practices. ,, Veridiam was one of nine winners,...mpanies, honored at the recent awards ceremony. Sa...
(Date:11/20/2009)...LE, Md., Nov. 20 Novavax...s priced an underwritten public offering of 6,800,...ublic of $3.30 per share. The approximately $21 m...riting discounts and commissions, will be used for...P-based vaccines, internal research and developmen...
Breaking Biology Technology:Pearl Therapeutics Appoints Howie Rosen to Board of Directors 2Amaizing: Corn genome decoded 2Amaizing: Corn genome decoded 3Amaizing: Corn genome decoded 4Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Novavax Prices Public Offering of Common Stock 2
Other News:
...or a decade now, ESA satellites have been continuo...rface. Worldwide fire maps based on this data are ...rough ESA's ATSR World Fire Atlas.... ...The ATSR ...l fire atlas ever developed provides data approxi...
.....Many people are aware that heavy drinking during.....Recent analysis shows that even light to moderat...second trimester, can significantly predict defici... was especially pronounced among African-American ...
...RLANDO May 24, 2006 -- Researchers have identifie...m to invade and infect human arterial cells, offer...ction between gum disease and heart disease. Scie..., present their findings today at the 106th Genera...
The American Chemical Society (ACS) News Service Press Package is your access point for discoveries in fields ranging from astronomy to zoology, which are reported in the 35 journals of the American C
World fire maps now available online in near-real time 2Light-to-moderate prenatal alcohol exposure can lead to cognitive deficits 10 years later 2Light-to-moderate prenatal alcohol exposure can lead to cognitive deficits 10 years later 3ACS weekly press package May 8, 2006 2ACS weekly press package May 8, 2006 3ACS weekly press package May 8, 2006 4ACS weekly press package May 8, 2006 5ACS weekly press package May 8, 2006 6ACS weekly press package May 8, 2006 7
... Ph.D., Professor and Director of the Del E. Webb ...nstitute, was awarded the prestigious Ernst Jung P...amburg, Germany. Endowed by German industrialist ...ally in recognition of discoveries that have a maj...
...m encephalopathies (TSEs), such as bovine spongifo...p, and Creutzfeldt-Jakob disease (CJD) in humans, ...m the deposition of a misfolded form of the prion ...system. Accumulation of PrPSc can also be found i...
A recent discovery provides new information about critical cellular signals that may be involved in autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. Scientists h
San Francisco, Calif. May 18, 2004 The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced today it has completed enrollment and treatment of 667 patient
Stuart Lipton honored with Jung Prize for Medicine 2Protein may reduce susceptibility to autoimmune disease 2OneWorld Health completes enrollment, treatment in Phase III India trial 2